You are here

Daniel Allar
 - CorPath GRX robotic system
Cardiovascular Business

Already approved for robot-assisted PCI, Corindus Vascular Robotics’ CorPath GRX System is now cleared by the FDA for peripheral vascular interventions (PVIs). The system is the first to receive FDA clearance for both procedures.

Cardiovascular Business

Google researchers are testing an artificial intelligence (AI) platform that aims to predict a person’s risk of heart attack or stroke by examining images of the patient’s retina. They hope this method can eventually replace more invasive techniques for predicting cardiovascular disease.

 - hacker
Cardiovascular Business

The clinical benefit patients gain from remote monitoring with implantable electronic devices far outweighs the risk of the devices being hacked, according to a paper published Feb. 20 by the American College of Cardiology’s Electrophysiology Council.

 - Patient monitoring
Cardiovascular Business

Young women presenting to the hospital with acute myocardial infarction (AMI) report more non-chest related symptoms than men. Perhaps as a result of this complexity, patients and physicians are less likely to perceive those early symptoms as heart-related, according to a study published Feb. 19 in Circulation.

 - baby, pediatric
Cardiovascular Business

Children who survive cardiac surgery as infants have a 20-fold risk of hearing loss when compared to peers without heart defects, according to a study in the Journal of Pediatrics.

Cardiovascular Business

Babies who experience stroke can flip their language center to the opposite, uninjured side of the brain, according to a study of 12 perinatal stroke survivors presented at the American Association for the Advancement of Science annual conference in Austin, Texas.

 - c-biga
Cardiovascular Business

To identify the most pressing topics for industry leaders, Cardiovascular Business spoke to course director Cathie Biga, MSN, RN, about the agenda for the 2018 American College of Cardiology Cardiovascular Summit.

 - FDAlogo
Cardiovascular Business

The FDA on Feb. 15 announced Stryker’s Trevo Retriever clot-removal device can be used up to 24 hours after stroke onset, mirroring the American Heart Association and American Stroke Association’s recently updated guidelines expanding the window for mechanical thrombectomy from 6 to 24 hours.

Cardiovascular Business

Heart valve disorders are associated with the highest hospital costs per inpatient stay, according to the Healthcare Cost and Utilization Project (HCUP), running up an average tab of $41,878 per visit.

 - VIz.ai logo
Cardiovascular Business

The FDA cleared Viz.ai’s clinical support tool on Feb. 13, allowing the software that alerts clinicians to the possibility of a stroke to be marketed in the United States.